Aptevo Therapeutics (APVO) vs Silexion Therapeutics (SLXN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Aptevo Therapeutics is the larger company by market cap ($3.2 million vs $3.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APVO | SLXN |
|---|---|---|
| Share price | $1.79 | $0.2146 |
| Market cap | $3.24M | $3.11M |
| 1-day change | -0.56% | -8.64% |
| P/E ratio (TTM) | 0.03 | — |
| EPS (TTM) | $66.59 | $-24.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.06 | $39.40 |
| 52-week low | $1.37 | $0.2079 |
| Distance from 52-week high | -94.05% | -99.46% |
| Analyst consensus | none | none |
| Avg. price target upside | +1324.58% | +2229.92% |
| Average volume | 92.25K | 10.05M |
| Shares outstanding | 1.81M | 14.47M |
| Employees | 33 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aptevo Therapeutics
APVO stock →Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Silexion Therapeutics
SLXN stock →Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 13 employees
APVO vs SLXN FAQ
Which is bigger, Aptevo Therapeutics or Silexion Therapeutics?
Aptevo Therapeutics (APVO) is larger, with a market capitalization of $3.24M compared with $3.11M for Silexion Therapeutics (SLXN).
Are Aptevo Therapeutics and Silexion Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Aptevo Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Silexion Therapeutics.